contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


change-in-the-biohit-oyjs-management-team

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Biohit operates in the medical technology sector. The company develops and manufactures laboratory equipment, consumables and diagnostic analysis systems adapted for research, healthcare and industrial laboratories. In addition to its main business, it offers technical support, maintenance and training services within the aforementioned field of work. The largest operations are conducted in the Nordic market. The company has its headquarters in Helsinki.

Vi lavede en lille statusopdatering om Biohit med Antti.                    Inderes              Biohit kasvaa ja kannattaa - Inderes    Aika: 27.01.2026 klo 16.37 Biohitin osake sekä liiketoiminta ovat kehittyneet erinomaisesti viimeisen kolmen vuoden aikana. Onko osakkeessa vielä potentiaalia?

Omsætningen i H1 var 7,4 M€ og steg ikke fra året før. H2 2024 var 6,9 M€. Blot det at nå den nedre ende af guidancen på 15,7 M€ ville betyde en vækst i omsætningen på over 20 % for resten af året (H2 > 8,3 M€). Det ville også love godt for resultatet.

Tre uger efter årsskiftet, og der er i hvert fald ikke kommet nogen nedjustering endnu. Omsætnings-guidance for sidste år var 15,7-17,1 mio. Inderes’ omsætningsestimat, som blev hævet for en uge siden, ligger lige på den nedre grænse af denne guidance på 15,7 mio. Forventningerne til H2 stiger i hvert fald hos mig.

Antti har udarbejdet en ny selskabsrapport om Biohit.  Biohits aktiekurs er faldet, og dermed er afkast/risiko-forholdet igen blevet attraktivt. Vi hæver vores anbefaling til tilføj (tidl. mindska) og fastholder vores kursmål på 3,7 euro. Der er ikke sket ændringer i selskabets udsigter, men vi foretager små justeringer i vores estimater for de kommende år. Ændringerne har ingen konkret betydning for værdiansættelsen. Vi forventer, at den defensive lønsomme vækst fortsætter for Biohit i det indeværende år. Situationen i Mellemøsten og udviklingen i tilgodehavender fra salg skaber usikkerhed for året.                   Inderes              Tartumme Biohitin tammialeen - Inderes    Biohitin osakekurssi on laskenut ja sen myötä tuotto-riskisuhde on kääntynyt jälleen houkuttelevaksi.

Nå, det forklarer en del, tak for det! Det giver alligevel ikke kuldegysninger.

Hendolin arbejdede i Biohit i lederstillinger i årene 2007-2008, 2014-2017 og 2022-2026, så han har bestemt nået at gøre meget for selskabet, selvom han kun var i sin seneste stilling i halvandet år.

https://www.inderes.fi/releases/muutos-biohitin-johtoryhmassa. Nå, der kommer da i det mindste nogle nyheder indimellem. Vedkommende bestred desværre kun stillingen i ret kort tid, det ville være interessant at vide, om det er en indikator, og i så fald for hvad helt præcist

Biohit

Press ReleaseChange in the Biohit Oyj’s Management TeamPublishing on January 14, 2026 at 10:30 am local time (EET)Panu Hendolin, Chief Technology Officer (CTO) and a member of the management...

Press ReleaseChange in the Biohit Oyj’s Management TeamPublishing on January 14, 2026 at 10:30 am local time (EET)Panu Hendolin, Chief Technology Officer (CTO) and a member of the management team of Biohit Oyj, has resigned.The company thanks Mr. Hendolin for his contribution. During his long career at Biohit, he has supported the company’s development and the strengthening of its technological expertise.Kati Piironen has been appointed to the management team to succeed Mr. Hendolin. She serves as the company’s R&amp;D Director. Ms. Piironen has been employed by Biohit since 2024. She holds a PhD in pharmaceutical chemistry, and has broad experience in product development, particularly in diagnostic technologies. Her expertise supports the further development of the company’s research and development activities to meet future needs.The change takes effect immediately.Additional information:&nbsp; Jussi Hahtela, CEO, Biohit Oyj, tel. +358 50&nbsp;383 5948investor.relations@biohit.fi www.biohithealthcare.comBiohit in briefBiohit Oyj is a globally operating Finnish biotechnology company. Biohit mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group.&nbsp;<a href="https://www.globenewswire.com/Tracker?data=ciyb_iZ945H2z3sK3a9i7Zs03Nkj9jr5Brw7kC1tsoUye5PVgko06PC57Z9BVVT2pXUgp6sn-tswLd2MUgQOQc8UNXD2BkNm3L02XzRJ7XfJCPaPUqGS1mpI0NZinK5T">www.biohithealthcare.com</a>